A tighter archive for life-science signals.
Search once, then narrow by source or topic.
TGR5 as a target for acute kidney injury
TGR5 as a target for acute kidney injury
A humanized mouse mimics Fcγ receptor biology in antibody essays
A humanized mouse mimics Fcγ receptor biology in antibody essays
Kinoteck Therapeutics synthesizes WRN inhibitors for cancer
Kinoteck Therapeutics synthesizes WRN inhibitors for cancer
Regulatory actions for Feb. 3, 2026
Regulatory actions for Feb. 3, 2026
Switching off resistance: Lixa’s bold AMR bet
Switching off resistance: Lixa’s bold AMR bet
Why many global drugs never reach Japan
Why many global drugs never reach Japan
China NMPA approves Sciwind’s GLP-1 injection for diabetes
China NMPA approves Sciwind’s GLP-1 injection for diabetes
Elevar gets new CEO, files NDAs for lirafugratinib, rivoceranib
Elevar gets new CEO, files NDAs for lirafugratinib, rivoceranib
Amgen quits Kyowa Kirin deal, returns rocatinlimab
Amgen quits Kyowa Kirin deal, returns rocatinlimab
In the clinic for Feb. 2, 2026
In the clinic for Feb. 2, 2026
Other news to note for Feb. 2, 2026
Other news to note for Feb. 2, 2026
Regulatory actions for Feb. 2, 2026
Regulatory actions for Feb. 2, 2026
Money raised by biopharma
Money raised by biopharma
Biopharma money raised: Jan. 1-30, 2026
Biopharma money raised: Jan. 1-30, 2026
Regulatory clarity lifts Aquestive despite CRL for Anaphylm
Regulatory clarity lifts Aquestive despite CRL for Anaphylm
Biggest gainers and losers for Jan. 26-30, 2026
Biggest gainers and losers for Jan. 26-30, 2026
Sea4us patent discloses new oxazolidone-derived compounds for pain
Sea4us patent discloses new oxazolidone-derived compounds for pain
Astrazeneca reports GIPR antagonists
Astrazeneca reports GIPR antagonists
Brand directory, kept in view
A rolling strip of the companies, platforms, CROs and device makers that show up across the coverage.
Open about page